About Tishtha 100mg Injection
Tishtha 100mg Injection contains Nivolumab, an immunotherapy medication used to treat a variety of cancers, including skin cancer, lung cancer, kidney cancer, lymphoma, bladder cancer, esophageal cancer, and cancers of the urinary tract. It is commonly prescribed for patients whose cancer has returned or progressed despite previous treatments such as surgery, chemotherapy, radiation therapy, or other anticancer medications. Nivolumab belongs to a class of medicines known as immune checkpoint inhibitors and works by blocking specific proteins that can prevent the immune system from recognizing and attacking cancer cells. By enhancing the body's natural immune response, Tishtha 100mg Injection helps slow tumor growth, shrink cancer cells, and improve treatment outcomes. One of the major advantages of immunotherapy is its potential to provide long-lasting responses in some patients, even after treatment has been completed. However, this medication should not be used by individuals with a known allergy to Nivolumab or any of its ingredients. It should also be used with caution in patients with autoimmune disorders such as lupus or rheumatoid arthritis, as it may worsen these conditions by stimulating immune activity. Individuals with a history of organ transplantation should discuss the potential risks and benefits with their healthcare provider before starting treatment. Regular monitoring during therapy is essential to manage side effects and ensure the safe and effective use of Tishtha 100mg Injection.
Powerful Immunotherapy for Multiple CancersTishtha 100mg Injection contains Nivolumab, a modern immunotherapy solution used to combat a variety of cancers, including those of the skin, lung, kidney, and bladder. By harnessing the patient's immune system, it offers a targeted approach to destroying cancer cells, often resulting in improved treatment outcomes when compared to traditional chemotherapy.
Safe Packaging and Storage GuidelinesEach box of Tishtha 100mg Injection is supplied as one vial or a pre-filled syringe. For optimal efficacy, it should be stored in controlled room temperatures between 20C - 25C (68F - 77F). This ensures the medicine maintains its stability and potency until its expiration in 2028, providing peace of mind for healthcare providers and patients alike.
FAQ's of Tishtha 100mg Injection:
Q: How does Tishtha 100mg Injection help treat cancer?
A: Tishtha 100mg Injection, containing Nivolumab, works by enhancing the body's immune response to cancer cells. It targets specific proteins on cancer cells, making them more visible to the immune system and allowing for more effective destruction of malignant cells.
Q: What cancers can be treated with Tishtha 100mg Injection?
A: Tishtha 100mg Injection is indicated for the treatment of several cancers, including those of the skin (such as melanoma), lungs, kidney, lymph nodes, bladder, esophagus, and urinary tract.
Q: When should Tishtha 100mg Injection be administered?
A: This medication should be given according to a schedule set by your oncologist, typically in a clinical or hospital setting. Your doctor will determine the precise timing and frequency based on your type of cancer, medical condition, and response to previous treatments.
Q: Where should Tishtha 100mg Injection be stored before use?
A: Tishtha 100mg Injection must be stored at controlled room temperature, specifically between 20C and 25C (68F to 77F), in its original packaging until ready for use.
Q: What is the process for receiving Tishtha 100mg Injection?
A: A healthcare professional will administer Tishtha 100mg Injection as an intravenous infusion, usually in a clinic or hospital. The doctor will closely monitor the infusion and adjust future doses as necessary.
Q: What are the primary benefits of using Tishtha 100mg Injection?
A: This medication offers a targeted immunotherapy approach, often leading to improved outcomes and fewer side effects compared to conventional chemotherapy. Tishtha 100mg aims to provide a more effective and tolerable cancer treatment option.